

Advancing Priority Research on the Middle East Respiratory Syndrome Coronavirus

David F. Hui¹, Alimuddin Zumla²

¹Department of Infection, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, and NIHR Biomedical Research Centre, University College London Hospitals, London, United Kingdom

²Division of Respiratory Medicine and Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong

Correspondence to: Professor Alimuddin Zumla, Professor of Infectious Diseases and International Health, University College London, UCL Royal Free Campus, Division of Infection and Immunity, Centre for Clinical Microbiology, Royal Free Hospital, 2nd floor, Rowland Hill Street, London NW3 2P, United Kingdom. Tel: +44-7901 638375, Email: a.zumla@ucl.ac.uk or a.i.zumla@gmail.com

Over a year since its first discovery, a new human disease, the Middle East Respiratory Syndrome (MERS), continues to be of major international concern due to its high fatality rate and lack of knowledge on its primary source and mode of transmission. It is caused by a novel coronavirus MERS-CoV, initially named 2cEMC/2012 (HCoV-EMC) (1) and subsequently renamed as MERS-CoV(2) after international consensus (3). It presents as a spectrum of respiratory diseases and is associated with a high case fatality rate in persons with co-morbid medical conditions. (4,5), The first MERS case report was from Jeddah, Kingdom of Saudi Arabia (KSA) in September 2012 when MERS-CoV was isolated from a Saudi Arabian patient who died from a severe respiratory illness and multi-organ failure (2). As of **October 30th 2013**, there have been **145** laboratory-confirmed cases of MERS with **62** deaths (**42%** case fatality rate), reported from 9 countries to the World Health Organization (WHO) (6,7). All cases were linked directly or indirectly to one of four countries in the Middle East: KSA, Qatar, Jordan, and the United Arab Emirates (UAE). Five countries outside the Middle East, The United Kingdom, France, Italy, Germany and Tunisia, have reported patients who were either transferred for care or returned from a visit to the Middle East and subsequently became ill. Four of these countries, Italy, France, Tunisia and the United Kingdom, have had secondary cases linked to the initial imported case (6, 7). The majority of MERS-CoV cases to date (**121 out of 145** cases) have been reported from KSA, occurring as family (8) or hospital (5) clusters, sporadic community cases, or detected with mild disease or asymptomatic infection on screening of health care workers who were in contact with MERS cases (9). Human-to-human transmission of MERS-CoV has been well documented in KSA (5,10), England(11), France(12), Tunisia and Italy (6,12). The clusters detected so far are mostly small and there have been no reports of sustained transmission of MERS-CoV within the community.

Despite several multi-country collaborative research efforts with the government of KSA to define the demographic, clinical features, mode of transmission and epidemiology of family and hospital clusters (4,5-10), several important priority research questions remain unanswered. It is unclear what the primary source and primary mode of transmission of MERS-CoV to humans is - critical information which is essential for developing interventions for reducing the risk of transmission, defining the epidemiology and developing effective control measures. The cellular receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (DPP4, CD26)(11), and the structure of the receptor binding domain of the virus spike protein complexed with DPP4 was rapidly identified (13). The receptor is conserved across mammals, suggesting several animal hosts, although no definitive animal reservoir for MERS-CoV has been identified. Studies of MERS-CoV genomes from

MERS cases suggest the existence of a direct animal reservoir for MERS-CoV (10).

Bats are usual suspects for transmission of coronaviruses. A recent study (14) identified a small 190 nt sequence of MERS-CoV, with maximum possibility of identity, in a fecal sample from an Egyptian tomb bat. Serological studies in animals have detected antibodies against the spike protein of betacoronaviruses (15), and this finding has led researchers to conclude that MERS has at some time passed into camels (16). Support for this theory comes from detection of anti-MERS-CoV antibodies in camels in Oman and Spain (17). The authors of that study concluded that MERS-CoV or a virus very similar to MERS-CoV has widely circulated among camels in Oman. However, this does not provide definitive proof that camels are a source of MERS-CoV since viral nucleic acid tests of serum and fecal samples did not reveal presence of MERS-CoV or viral particles. Furthermore, no human MERS cases have been reported from Oman, which borders KSA. Coronaviruses constitute a large family of viruses that may cause a range of illnesses in humans, as well as a number of diseases in a variety of animals. Previous studies have shown, for example, that coronaviruses can cause severe symptoms in newborn camels (18), and it is likely that cross-reactive antibodies with a related coronavirus to MERS-CoV occurred. Further research is required to identify the specific source or reservoir of MERS-CoV, any intermediate animal host(s) or other inanimate food source, and the mode of transmission to humans.

Despite these studies indicating the presence of anti-MERS-CoV antibodies to be widespread within animal populations in the Middle East, human studies have not shown widespread infection in local populations. The article by AsadAburizazaiza and colleagues (19) in this issue of *the Journal of Infectious Diseases* contains data from a study where a staged approach utilising an immunofluorescence assay (IFA), differential recombinant IFA, and a plaque reduction serum neutralisation assay was used to detect MERS-CoV antibodies in sera from 130 blood donors and 226 abattoir workers in Jeddah and Makkah during the 2012 Hajj pilgrimage. They conclude that there was no evidence of MERS-CoV circulation in the region, and suggest that a large percentage of the population are considered non-immune. Although the data appear concordant with the apparent absence of MERS-CoV when screened by rt-PCR in 154 French pilgrims returning from the 2012 Hajj(20), these antibody studies do not provide proof of absence or presence of MERS-CoV because of limitations imposed by the restricted study design and small numbers studied. Since several groups have developed a range of serological tests for detecting MERS-CoV, there is a need to independently evaluate and validate the sensitivity and specificity of these assays against a blinded

panel of sera from known positive and negative MERS cases, and against other tests that can identify presence of MERS-CoV specific nucleic acids. The availability of accurate, validated, sensitive and specific serological tests is essential for conducting case control studies which are crucial to accurately defining the epidemiology, the potential impact of the MERS-CoV outbreak and for surveillance purposes.

Many important questions about MERS-CoV remain unanswered (4). The natural history, pathogenesis, host susceptibility factors, viral virulence, viral kinetics, periods of infectiousness, underlying mechanisms of protective immunity, optimal treatments and factors governing treatment outcome remain unclear. Absence of these basic data is hindering the development of drug treatment, adjunct therapies, specific diagnostics, biomarkers, and vaccines. Whereas an animal source of the virus appears the most likely source, the route of transmission could be either direct or indirect contact, or consumption of a contaminated food or food product. Available data indicate that MERS-CoV has not yet readily adapted to infecting humans, and human to human transmission is not sufficient or efficient for pandemic potential (21). Despite extensive investigations and screening testing of contacts of MERS cases in KSA, only a few instances of transmission have been identified in health care workers (9). Post mortem and histological studies have not been available and introducing these, even non-invasive autopsies (22), would help advance the scientific knowledge base.

The availability of an animal model of MERS-CoV infection and disease is essential for understanding the pathogenesis, natural history, immune responses and for developing effective therapies. In this issue of JID, Tanfeng Yao *and colleagues* (23) describe an animal model of MERS which they produced by using intratracheal infection of Rhesus Macaque monkeys with MERS-CoV, resulting in the development of pneumonia, and showed MERS-CoV replication was largely restricted to the lower respiratory tract. The infected monkeys showed clinical signs of disease, virus replication, histological changes, and neutralising antibody production. Another recent study of a Rhesus Macaque monkey model of MERS-CoV infection has shown similar findings (24). Using a combination of intratracheal, ocular, oral, and intranasal inoculation with 7×10^6 50% tissue culture infectious dose of the MERS-CoV isolate HCoV-EMC/2012, the monkeys developed a transient lower respiratory tract infection. Clinical signs, virus shedding, virus replication in respiratory tissues, gene expression, and cytokine and chemokine profiles peaked early in infection and decreased over time. MERS-CoV caused a mild to marked multifocal interstitial pneumonia, with MERS-CoV

replication occurring mainly in alveolar pneumocytes. This tropism of MERS-CoV for the lower respiratory tract may explain the severity of the disease observed in humans and the limited human-to-human transmission.

The MERS-CoV rhesus macaque model will be instrumental in developing and testing vaccine and treatment options for an emerging viral pathogen with pandemic potential. Specific therapeutic interventions for MERS-CoV are not available and have not been clinically evaluated. Current patient management relies exclusively on supportive care, which, given the high case-fatality rate recorded so far (4), is not highly effective. Empiric treatment with anti-viral drugs or drug regimens, or immune therapies which were used for SARS (25) require clinical evaluation. A recent study (26) indicates that a two-drug combination may be effective against MERS-CoV. Using small compound-based forward chemical genetics to screen known drugs against influenza and also interferons, nelfinavir, lopinavir, and nitazoxanide because of their reported anti-coronavirus effects, the authors identified mycophenolic acid, ribavirin and interferons as exhibiting *in-vitro* anti-MERS-CoV activity, and showed that the antiviral effect of interferon-beta-1b was stronger than that of ribavirin. Using the rhesus macaque monkey model for MERS-CoV infection, Falzarano et al (27) showed that treatment with IFN- α 2b and ribavirin reduced virus replication, moderated the host response and improved clinical outcome. Clinical evaluation of IFN- α 2b and ribavirin should be considered for severe cases of MERS. Other treatment options for MERS-CoV that require further investigation include the cyclophilin inhibitors (28,29) and convalescent plasma (30) from patients who have fully recovered from MERS-CoV. Convalescent plasma and related hyper-immune globulin may have had some apparent success during SARS (31) and during the influenza pandemic due to A(H1N1)(32).

With the current knowledge gaps, it is unknown whether MERS-CoV will remain a disease restricted to the Middle East with intermittent, sporadic outbreaks; progress to becoming a global pandemic; or burn out with time. Many priority research questions remain to be answered before the true pandemic potential and global impact of MERS-CoV can be accurately determined. Almost all patients who died or those who have been hospitalized with severe disease had other co-morbid medical conditions (4). The mortality rate and severity of disease are exaggerated to some degree by detection of such cases. The case-fatality rate has fallen in recent months due to the detection of milder and asymptomatic cases (7). Determining the true spectrum of MERS-CoV infection and disease severity requires widespread viral testing, collection of clinical data, and serologic studies.

Case control studies are essential for defining the MERS-CoV outbreak and validated accurate serological tests which are sensitive and specific are required to facilitate these. The most ominous characteristic of pandemic MERS-CoV strains would be progression to efficient human-to-human transmission. The number of sporadic MERS cases being reported has been small and indicates that the virus appears not readily capable of rapid human to human transmission. Despite extensive investigation and testing of hundreds of contacts by the KSA Ministry of health, only a few instances of transmission to health care workers or family contacts were identified (6,7,9). Sequencing studies of all MERS-CoV genomes may reveal genetic features that will tell us if MERS-CoV has the ability to mutate and spread efficiently. The rapid sharing of genetic sequence information(10, 34) will provide valuable insights into the understanding of the molecular characteristics, transmission dynamics, which will assist in defining species specificity, ascertaining mutation rates and virulence, and also enabling discovery of drug targets, novel drugs, diagnostics and vaccines.

Two million pilgrims from over 180 countries, and 1 million local KSA pilgrims have recently visited Makkah and Madinah, KSA, to perform the 2013 annual Hajj pilgrimage, and have returned home after stays of between 2 and 8 weeks. Millions of others will visit KSA throughout the year for the mini-pilgrimage UMRAH. While answers to priority research on MERS-CoV are being sought, the need for more coordinated surveillance and improved effective international co-operation between WHO, Middle eastern governments, academic stakeholders and pharmaceutical companies remains critical to tackling this ominous threat (35).Major knowledge gaps remain for the current MERS-CoV outbreak over a year after its first discovery. Once again this illustrates that there remains a need for establishment of robust public health and clinical infrastructures, effective global consortia, and a stable funding source for rapid and effective definition of new infectious diseases outbreaks and threats, and for conduct of priority research, preparedness, and response.

Conflicts of interest: Authors declare no conflicts of interest

Funding source: The authors declare no specific funding source

References

1. Severe respiratory illness associated with a novel coronavirus-Saudi Arabia and Qatar, 2012. *MMWR Morb Mortal Wkly Rep.* 2012; 61(40): 820.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med.* 2012; 367(19): 1814-20.
3. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. *J Virol.* 2013 Jul;87(14):7790-2.
4. Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis.* 2013 Sep;13(9):752-61.
5. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeh AA, Cummings DA, et al. Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus. *N Engl J Med.* 2013.369:407-416.
6. WHO update. Middle East respiratory syndrome coronavirus (MERS-CoV) - update 29 October, 2013.
http://www.who.int/csr/don/2013_10_29a/en/index.html
http://www.who.int/csr/don/2013_09_20/en/index.html accessed 30 October, 2013.
7. Updated Information on the Epidemiology of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection and Guidance for the Public, Clinicians, and Public Health Authorities, 2012-2013. Centers for Disease Control and Prevention (CDC). *MMWR Morb Mortal Wkly Rep.* 2013 Sep 27;62(38):793-796.
8. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeh AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. *N Engl J Med.* 2013; 368(26): 2487-94.
9. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. *N Engl J Med.* 2013 Aug 29;369(9):884-6.
10. Cotten M, Watson SJ, Kellam P, Al-Rabeeh AA, Makhdoom HQ, Assiri A, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. *Lancet.* 2013 Sep 19. doi:pii: S0140-6736(13)61887-5. 10.1016/S0140-6736(13)61887-5.
11. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. *Euro Surveill.* 2013; 18(11): 20427.
12. Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahar N, Lemaire X, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. *Lancet.* 2013; 381(9885): 2265-72.
13. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature.* 2013; 495(7440): 251-4.
14. Memish ZA, Mishra N, Olival KJ, Fagbo SF, Kapoor V, Epstein JH et al. Middle East Respiratory Syndrome Coronavirus in bats, Saudi Arabia. *Emerging Infectious diseases* 2013;19:11: Nov –in press
15. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. *Journal of Virology.* 2013; 87(10): 5502-11.
16. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via

- sequential proteolytic cleavage at two distinct sites. *Proc Natl Acad Sci USA*. 2009; 106(14): 5871-6.
17. Reusken CB, Haagmans BL, Muller MA, Gutierrez C, Godeke GJ, Meyer B, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. *Lancet Infect Dis*. 2013.
 18. Crossley BM, Mock RE, Callison SA, Hietala SK. Identification and Characterization of a Novel Alpaca Respiratory Coronavirus Most Closely Related to the Human Coronavirus 229E. *Viruses*. 2012 December; 4(12): 3689–3700.
 19. Aburizaiza AS, Mattes FM, Azhar E, Ahmed HM, Muth D, Meyer B, et al. Investigation of anti-MERS-Coronavirus antibodies in blood donors and abattoir workers in Jeddah and Makkah. Kingdom of Saudi Arabia, fall 2012. *Journal of Infectious Diseases* 2013: (in press)
 20. Gautret P, Charrel R, Belhouchat K, Drali T, Benkouiten S, Nougairede A, et al. Lack of nasal carriage of novel corona virus (HCoV-EMC) in French Hajj pilgrims returning from the Hajj 2012, despite a high rate of respiratory symptoms. *Clin Microbiol Infect*. 2013 Jul;19(7):E315-7
 21. Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. *Lancet*. 2013. Aug 24;382(9893):694-9. doi: 10.1016/S0140-6736(13)61492-0. Epub 2013 Jul 5.
 22. Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: a review of autopsy studies. *Curr Opin Pulm Med*. 2013 May;19(3):229-37.
 23. Yao Y, Bao L, Deng W, Xu L, Li F, Lv Q, et al. An animal model of MERS produced by infection of Rhesus Macaques with MERS coronavirus. *Journal of Infectious Diseases* 2013: -inpress.
 24. de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. September 23, 2013, doi: 10.1073/pnas.
 25. Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy. *Int J Infect Dis*. 2013 Oct;17(10):e792-8. doi: 10.1016/j.ijid.2013.07.002. Epub 2013 Aug 29.
 26. Chan JFW, Chan KH Broad spectrum antivirals for the emerging Middle East Respiratory Syndrome Coronavirus. *J Infection* 30 Oct 2013: -in press.
 27. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon- α 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. *Nat Med*. 2013 Sep 8. doi: 10.1038/nm.3362. [Epub ahead of print]
 28. De Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Narayanan K, Makino S, Snidjer EJ, van Hemert MJ. Cyclosporin A inhibits the replication of diverse coronaviruses. *J of Gen Virology* 2011;92:2542-2548
 29. Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. *Viruses* 2013: 5(5) 1250-1260.
 30. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect*. 2004 Jul;10(7):676-8.
 31. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005 Jan;24(1):44-6.

32. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, et al. Hyperimmune IV Immunoglobulin Treatment: A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza A(H1N1) Infection. *Chest*. 2013 Aug;144(2):464-73.
33. Rambaut A. Novel human betacoronavirus molecular evolutionary analyses.
<http://epidemic.bio.ed.ac.uk/coronaviruses> accessed 6th October, 2013.
34. Zumla A. Equitable partnerships for tackling killer infectious diseases. *Lancet Global Health* 2013:
<http://globalhealth.thelancet.com/2013/07/26/equitable-partnerships-tackling-killer-infectious-diseases> accessed October 7th 2013.